Imagine you’re fighting a war, and your most feared enemy suddenly switches sides to fight alongside you. That’s exactly what’s happening in cancer research labs around the world, where scientists are turning our oldest microscopic adversaries – viruses – into targeted tools against tumors.

Viruses can be considered the ultimate villains, agents of disease and disruption. But the traits that make viruses so destructive to healthy cells can be reprogrammed to selectively hunt down and destroy cancer cells while leaving normal tissue untouched.

This approach may seem paradoxical. How can something that causes disease become part of a cure? The answer lies in what viruses do best: hijacking cellular machinery, triggering immune responses, and targeting specific cell types with remarkable precision.

The Cellular Trojan Horses

Oncolytic viruses (OVs) are either naturally occurring or genetically engineered viruses that replicate preferentially in cancer cells, leading to their destruction through direct cell killing, immune activation, or both. Some viruses happen to exploit cancer cell vulnerabilities better than they can infect healthy cells.

The concept isn’t entirely new. As early as the 1900s, doctors noticed something curious: patients with advanced cancers would sometimes see their tumors shrink after catching viral infections like measles or influenza. These observations planted the seed for what would become oncolytic virotherapy.

But it wasn’t until molecular virology and genetic engineering came along that researchers could design viruses to act as precise, controllable anticancer treatments rather than relying on chance encounters.

The Three-Pronged Attack

Oncolytic viral therapy works like a coordinated response, combining direct cell killing with immune system activation. Here’s how it unfolds:

Exploiting Cancer’s Weak Spots

Because many tumours have loss‑of‑function mutations, such as crippled type I interferon (antiviral) signalling, oncolytic viruses can enter these cells, multiply unchecked, and trigger cell lysis. The burst releases thousands of new virions that move on to infect nearby cancer cells while normal cells, with intact interferon defences, halt infection.

Calling in Backup

When cancer cells explode from viral infection, they don’t just die quietly. They release tumor antigens and cellular alarm signals like calreticulin and HMGB1 – like sending up a flare that say “cancer here!”

These molecular distress signals recruit the body’s immune system: dendritic cells, natural killer cells, and T cells rush to the tumor site. Suddenly, a “cold” tumor that was hiding from the immune system becomes a “hot” target that attracts immune attention from throughout the body.

Delivering the Perfect Payload

Many engineered OVs act as delivery trucks, carrying therapeutic genes directly into cancer cells. A prime example is GM-CSF (Granulocyte-macrophage colony-stimulating factor), a protein that supercharges immune cell production. Other viral couriers deliver genes that trigger cell death (like TRAIL) or starve tumors by blocking blood vessel formation (like Endostatin).

Some modifications are particularly clever. Take Pexa-Vec (JX-594), a vaccinia-based virus tested extensively in clinical trials. Scientists replaced the viral thymidine kinase gene with human GM-CSF, creating a double-edged sword: the GM-CSF boosts immune responses while the missing thymidine kinase makes the virus dependent on cancer cells for replication – since only cancer cells produce enough of this protein to support viral growth.

Viral Platforms in Development

Each oncolytic virus platform brings distinct mechanisms, clinical advantages, and therapeutic applications to the cancer treatment landscape:

Herpes Simplex Virus (HSV)

The herpes simplex virus (HSV) has led to the development of the most widely approved cancer-fighting viral therapy to date. T-VEC is an improved version of HSV that has been modified by removing two genes (ICP34.5 and ICP47), allowing it to specifically target cancer cells while also producing a protein (GM-CSF) that helps activate the immune system. In a large clinical trial called OPTiM, 16.3% of advanced skin cancer patients showed lasting improvement with T-VEC, compared to only 2.1% of patients treated with GM-CSF alone. Patients treated with T-VEC survived for an average of 23.3 months. The therapy works by taking advantage of weaknesses common in cancer cells, specifically their impaired defense systems against viruses, which allows the modified virus to multiply primarily in tumor cells. A newer version called DELYTACT, which has been approved in Japan to treat aggressive brain tumors, includes additional genetic modifications to make it safer while maintaining its ability to kill cancer cells.

Adenovirus

Modified viruses called adenoviruses were among the first cancer-fighting viruses tested in patients, with H101 becoming the first approved cancer-fighting virus in China (2005) for treating head and neck cancers. ONYX-015 is a modified virus designed to target and destroy cancer cells with damaged p53 (a key protein that normally prevents cancer growth). However, later studies revealed that the virus’s effectiveness wasn’t due to its interaction with p53, but rather because of changes in how the virus transports genetic material in healthy cells. Clinical trials for H101 showed that 79% of patients responded positively when the virus was combined with standard chemotherapy drugs, compared to 40% for chemotherapy alone. Newer versions of these viruses, like ColoAd1, are designed to attack cancer cells through multiple pathways and can work better when given through the bloodstream. Clinical studies have shown these viruses can reach and multiply within tumors even when administered through a simple injection into a vein.

Reovirus

The natural virus strain T3D (commercially developed as REOLYSIN/pelareorep) specifically targets cancer cells by taking advantage of a common feature found in many human cancers – an overactive cellular growth signal called Ras. The virus works selectively because cancer cells with active Ras can block a specific defensive protein (PKR) that would normally stop viral growth, allowing the virus to multiply freely in cancer cells. This treatment approach has been shown to be safe in more than 26 clinical trials and has received special FDA status for treating several hard-to-treat cancers, including brain tumors, ovarian cancer, and pancreatic cancer.

Vaccinia Virus

Treatment platforms based on the vaccinia virus, such as Pexa-Vec (JX-594), take advantage of the virus’s large genetic storage capacity (190kb) to carry multiple therapeutic genes while still being able to multiply effectively in cancer cells. The virus naturally targets rapidly growing cells, and researchers have modified its genes by removing a specific enzyme (thymidine kinase), creating two ways to specifically target cancer cells. Pexa-Vec stuides have shown that higher doses led to stronger anti-cancer effects.

Measles Virus & Others

Weakened measles virus strains naturally target cancer cells that have specific proteins (CD46 and SLAM) on their surface. Scientists have created modified versions, like MV-NIS, which can both attack cancer cells and allow doctors to track the virus’s activity in real-time through medical imaging. Similarly, Newcastle Disease Virus naturally attacks human cancer cells while largely sparing healthy cells. Another virus type, Vesicular Stomatitis Virus, can effectively kill many different kinds of cancer cells, but researchers need to carefully modify it to prevent potential harm to nerve tissue.

Each platform’s clinical development continues to focus on combination strategies with checkpoint inhibitors, chemotherapy, and radiation therapy to maximize therapeutic indices while overcoming delivery and immune-mediated clearance challenges.

From Lab Bench to Bedside

Several oncolytic viruses have already made the leap from experimental therapy to approved treatment:

The cancer-fighting virus T-VEC (sold as Imlygic) is leading the field as the most thoroughly tested virus-based treatment, having gained approval from medical authorities in the US, Europe, and Japan. This modified cold sore virus is engineered to produce an immune system-boosting protein and was first used to treat advanced skin cancer (melanoma) that didn’t respond to other treatments. The encouraging results have led researchers to test it against other types of cancer.

H101 (Oncorine) broke ground as the first approved oncolytic virus, gaining approval in China in 2005 for head and neck cancers when combined with chemotherapy.

Delytact (G47Δ) has been granted approval for the treatment of malignant glioma, proving these therapies can tackle even aggressive brain tumors.

Delivery Challenges

Getting these viral therapies to their targets remains one of the biggest challenges. How do you ensure they reach the right place?

Direct injection into tumors works well for accessible cancers – like placing medicine exactly where it’s needed. Intravenous delivery allows treatment of widespread disease, though the body’s immune defenses often clear the viruses before they reach their targets.

More targeted approaches include intravesical delivery (directly into the bladder for localized cancers) and intrathecal injection (into spinal fluid for brain tumors).

The Power of Partnership

The most exciting developments combine OVs with other cancer therapies. Pairing an oncolytic virus with immune checkpoint inhibitors – drugs that release the brakes on immune responses – creates a powerful combination. The virus heats up the tumor environment while checkpoint inhibitors ensure the immune system can deliver the final therapeutic impact.

Clinical trials combining T-VEC with pembrolizumab have shown that a tag-team approach can be more effective than either treatment alone.

The Challenges Ahead

Despite their promise, oncolytic viruses face real hurdles. Delivery often fails as the immune system clears viruses before they reach tumors. The tumor environment itself poses challenges – it’s often immunosuppressive, oxygen-starved, and physically dense, restricting viral spread.

Pre-existing immunity adds another layer of complexity. Many patients already have antibodies against common viral platforms like HSV or adenovirus, potentially neutralizing treatments before they can work.

But scientists are creative problem-solvers. One ingenious approach involves loading viruses into mesenchymal stem cells (MSCs) – naturally tumor-seeking cells that can act as Trojan horses, delivering their viral cargo while shielding it from immune detection.

These innovations come with trade-offs: increased complexity means higher costs, longer development times, and more regulatory hurdles to navigate.

Looking Ahead

Turning viruses from foes into cancer-fighting allies represents one of medicine’s most elegant reversals. As researchers continue refining these therapies, the potential applications seem limitless – from enhancing existing treatments to tackling previously untreatable cancers.